Sign in

PrECOG

@precogonc.bsky.social
44 followers 60 following 78 posts

Innovative cancer research studies developed through industry partnerships and networks. Supporting ECOG-ACRIN's efforts to advance cancer care

PostsRepliesMedia
PrECOG @precogonc.bsky.social · 21/09/2026
Shout out to @OSUCCC_James & for enrolling its first patient in PrE0510, our phase 2 #ClinicalTrial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage #SmallCellLungCancer (#SCLC). Learn more: bit.ly/PrE0510
000
PrECOG @precogonc.bsky.social · 18/09/2026
Great work to @luriecancer.bsky.social for enrolling its first patient in PrE0510, our phase 2 #ClinicalTrial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage #SmallCellLungCancer (#SCLC). Learn more: bit.ly/PrE0510
000
PrECOG @precogonc.bsky.social · 02/09/2026
Northwestern is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell #LungCancer (#SCLC). Learn more here: bit.ly/PrE0510 #lcsm
000
PrECOG @precogonc.bsky.social · 29/07/2026
Gunderson Lutheran Medical Center is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell #LungCancer (#SCLC). Learn more here: bit.ly/PrE0510 #lcsm
000
PrECOG @precogonc.bsky.social · 09/07/2026
@upmchillmancc.bsky.social is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell #LungCancer (#SCLC). Learn more here: bit.ly/PrE0510 #lcsm
000
PrECOG @precogonc.bsky.social · 25/06/2026
Morristown Medical Center is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell #LungCancer (#SCLC). Learn more here: bit.ly/PrE0510 #lcsm
000
PrECOG @precogonc.bsky.social · 24/06/2026
Marshfield Clinic Research Institute is enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 18/06/2026
University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell #LungCancer (#SCLC). Learn more here: bit.ly/PrE0510 #lcsm
000
PrECOG @precogonc.bsky.social · 17/06/2026
The Ohio State University Comprehensive Cancer Center is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell #LungCancer (#SCLC). Learn more here: bit.ly/PrE0510 #lcsm
000
PrECOG @precogonc.bsky.social · 15/06/2026
@univmiami.bsky.social's Sylvester Cancer Center is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell #LungCancer (#SCLC). Learn more here: bit.ly/PrE0510 #lcsm
000
PrECOG @precogonc.bsky.social · 13/05/2026
Guthrie Medical Group is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510
000
PrECOG @precogonc.bsky.social · 30/04/2026
University of Virginia is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510.
000
PrECOG @precogonc.bsky.social · 28/04/2026
Kudos to @jeffersonuniv.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 24/04/2026
@rutgerscancer.bsky.social is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510.
000
PrECOG @precogonc.bsky.social · 24/04/2026
@foxchasecancer.bsky.social is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510
000
PrECOG @precogonc.bsky.social · 15/04/2026
Kudos to Aultman Health Foundation for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 02/04/2026
Great work to Montefiore for enrolling their first patient in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510
000
PrECOG @precogonc.bsky.social · 02/04/2026
Kudos to Aspirus Regional Cancer Care for enrolling their first patient in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510
000
PrECOG @precogonc.bsky.social · 01/04/2026
Great work to FirstHealth of the Carolinas-Moore Regional Hospital for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! Learn more: bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 27/03/2026
Kudos to @carlehealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 27/03/2026
FirstHealth of the Carolinas-Moore Regional Hospital is enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 24/03/2026
Great work to @choosesjc.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 17/03/2026
Kudos to Tufts Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
001
PrECOG @precogonc.bsky.social · 13/03/2026
@choosesjc.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
000
Reposted by PrECOG
ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 27/02/2026
#FindingsFriday: ICYMI, new data from @precogonc.bsky.social PrE0405, presented at #ASH25, showed that treatment with BR-VEN led to high response rates & promising CR rates for older patients w/ mantle cell #lymphoma. More: bit.ly/4aReE69 #MCL
bit.ly
Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)
BackgroundMantle cell lymphoma (MCL) is an incurable form of aggressive non-Hodgkin lymphoma. Treatment choice at diagnosis is based on tolerability o…
011
PrECOG @precogonc.bsky.social · 11/02/2026
UM Greenebaum Comprehensive Cancer Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 10/02/2026
Great work to ThedaCare for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 09/02/2026
Kudos to Montefiore Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 30/01/2026
New @nejm.org | PATINA ph 3 trial | Adding #Palbociclib significantly improves progression-free survival in patients w/ HR+ HER2+ metastatic #BreastCancer | Prolonged disease control for an incurable condition | bit.ly/PATINAresults
000
PrECOG @precogonc.bsky.social · 28/01/2026
Aspirus Cancer Center Wausua is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: clinicaltrials.gov/study/NCT070...
011
Reposted by PrECOG
ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 13/01/2026
DYK funding for NIH and NCI ends on 1/30? Act now & ask Congress to support sustainable, long-term funding for biomedical & #CancerResearch for FY26: bit.ly/3LpZJau
bit.ly
Federal Funding for Cancer Research
As Congress negotiates Fiscal Year 2025 appropriations bills, urge them to make cancer research a top priority.
011
PrECOG @precogonc.bsky.social · 23/12/2025
Kudos to Stanford Cancer Institute Palo Alto for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
101
PrECOG @precogonc.bsky.social · 17/12/2025
Great work to Baptist Memorial Health Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 15/12/2025
Tufts Medical Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
000
Reposted by PrECOG
ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 04/12/2025
At #ASH2025, ECOG-ACRIN & @precogonc.bsky.social researchers will present data that could improve treatments for #AML, #ALL, #MCL, #CLL and more. View our full guide to the meeting: bit.ly/4rtkbHp #BloodCancer #leukemia #lymphoma
bit.ly
Guide to ASH 2025: ECOG-ACRIN and PrECOG are set to reveal multiple blood cancer research discoveries
Lear more about the 11 in-depth scientific analyses aim to enhance the precision and safety of treatments for hematologic malignancies.
011
PrECOG @precogonc.bsky.social · 03/12/2025
Geisinger Cancer Institute is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 24/11/2025
Great work to Vanderbilt University Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 24/11/2025
@stanford-cancer.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 24/11/2025
In honor of #LungCancer Awareness Month, learn about PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Click here for more 👉 bit.ly/49xgUR3 #LCAM #LCSM
011
Reposted by PrECOG
ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 20/11/2025
On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25
bit.ly
Ongoing Trials: A closer look at ECOG-ACRIN’s clinical trials for patients with pancreatic conditions
For Pancreatic Cancer Awareness Month, we highlight two actively recruiting clinical trials for patients with pancreatic conditions
021
PrECOG @precogonc.bsky.social · 11/11/2025
Kudos to @virtuahealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
000
Reposted by PrECOG
ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 06/11/2025
The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S
bit.ly
Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma | OncLive
Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.
011
PrECOG @precogonc.bsky.social · 05/11/2025
Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
bit.ly
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
000
PrECOG @precogonc.bsky.social · 29/10/2025
Thomas Jefferson University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
000
PrECOG @precogonc.bsky.social · 15/10/2025
Marshfield Clinic is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
bit.ly
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
000
PrECOG @precogonc.bsky.social · 07/10/2025
Kudos to the following institutions for enrolling their first patients in #RealWorldData #PatientRegistry PrE1702: Sibley Memorial Hospital, Good Samaritan University Hospital, and Northwestern University! More info here: bit.ly/pre1702-study #LCSM #RWD #RWE
bit.ly
ClinicalTrials.gov
000
PrECOG @precogonc.bsky.social · 25/09/2025
Kudos to The Valley Hospital (Luckow Pavilion) for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
bit.ly
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
000
PrECOG @precogonc.bsky.social · 10/09/2025
Kudos to Aurora Saint Luke’s Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue
bit.ly
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
000
PrECOG @precogonc.bsky.social · 29/08/2025
Kudos to John H. Stroger, Jr. Hospital of Cook County for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
bit.ly
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
000
PrECOG @precogonc.bsky.social · 29/08/2025
University of Wisconsin Carbone Cancer Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue
bit.ly
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
000